Zimmer Biomet Holdings (NYSE:ZBH) : Traders are bullish on Zimmer Biomet Holdings (NYSE:ZBH) as it has outperformed the S&P 500 by a wide margin of 3.08% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.18%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.49% in the last 1 week, and is up 4.75% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 5.38% and the 50-Day Moving Average is 5.41%.
Zimmer Biomet Holdings (NYSE:ZBH): stock turned positive on Friday. Though the stock opened at $122.93, the bulls momentum made the stock top out at $124.98 level for the day. The stock recorded a low of $121.89 and closed the trading day at $124.89, in the green by 2.35%. The total traded volume for the day was 1,370,353. The stock had closed at $122.02 in the previous days trading.
In an insider trading activity, The officer (VP, Controller and CAO), of Zimmer Biomet Holdings, Inc., Collins Tony W. had unloaded 3,611 shares at $116.43 per share in a transaction on June 14, 2016. The total value of transaction was $420,429. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.